Blogs

Jun 26, 2018
Applied Clinical Trials
The late-June announcement that Ireland is joining the Beneluxa Initiative on Pharmaceutical Policy might suggest renewed vigour for the drive to equip national governments with more clout in their pricing negotiations with international drug firms.
Jun 25, 2018
Applied Clinical Trials
The general assumption that the Policy 0070 data releases were public data releases can be challenged since there is a mechanism to enforce the ToU, and this mechanism will continue to exist after the Agency moves to the Netherlands.
Jun 21, 2018
Applied Clinical Trials
How much does the EU really care about health, and about the infrastructure that is a precondition to successful healthcare and healthcare innovation?
Jun 18, 2018
Applied Clinical Trials
In this article, Moe will demonstrate a methodology that resulted in improving CRA performance.
Jun 18, 2018
Applied Clinical Trials
The right-to-try gale is now blowing at full strength in the US and is likely to prove a straw in the wind that could become a haystack.
Jun 13, 2018
Applied Clinical Trials
Liquid biopsy, typically non-invasive blood-based tests for circulating tumor DNA and circulating tumor cells, has been long-hyped as a potential game-changer for cancer treatment.
Jun 06, 2018
Applied Clinical Trials
To manage the growing scope and complexity of global disclosure regulations and trial transparency initiatives, companies are advised to create a cross-functional clinical transparency committee.
Jun 06, 2018
Applied Clinical Trials
In this article, we will discuss trends and challenges with medical monitoring clinical analytics, analyze the alignment of existing medical monitoring tools and technologies with ICH-E6 (R2) addendum guidelines, and discuss trends in medical monitoring insourcing and outsourcing models.
Jun 01, 2018
Applied Clinical Trials
Peter O’Donnell explores the convergence of policy and science in new vaccine R&D pursuits in Europe.
Jun 01, 2018
Applied Clinical Trials
Editor-in-Chief Lisa Henderson speak about therapeutic needs, rare diseases in children, and the SCORR Marketing survey on innovative or flexible trial designs.
native1_300x100
lorem ipsum